Browsing by Author Smith, Ian (Prof)

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
20072-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.Wilcken, Nicholas; Baselga, Jose (Prof); Bell, Richard (Prof); Bergh, Jonas (Prof); Cameron, David; Coleman, Robert; Dowsett, Mitch (Prof); Feyereislova, Andrea; Gelber, Richard D. (Prof); Gelmon, Karen (Prof); Goldhirsch, Aron (Prof); Guillaume, Sebastien; Harbeck, Nadia; Kaufmann, Manfred (Prof); Lopez, Roberto I; Mallmann, Peter (Prof); Mariani, Gabriella; Piccart-Gebhart, Martine J (Prof); Procter, Marion; Sanchez Rovira, Pedro; Smith, Ian (Prof); Untch, Michael (Prof); Wardley, Andrew; Wist, Erik (Prof); Western Clinical School: Medicine (Westmead)2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial., The Lancet, vol.369,(9555),2007,pp 29-36
2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyCoates, Alan; Chirgwin, Jacquie H; Colleoni, Marco; Forbes, John F.; Gelber, Richard D. (Prof); Giobbie-Hurder, Anita; Goldhirsch, Aron (Prof); Lang, Istvan; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Pienkowski, Tadeusz; Price, Karen N.; Regan, Meredith M.; Smith, Ian (Prof); Thurlimann, Beat; Wardley, Andrew; School of Public Health: Public HealthAnalyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study, Journal of Clinical Oncology, vol.29, 9, 2011,pp 1117-1124
2011Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-upCoates, Alan; Ejlertsen, Bent; Forbes, John F.; Gelber, Richard; Giobbie-Hurder, Anita; Goldhirsch, Aron; Lang, Istvan; Mauriac, Louis; Neven, Patrick; Price, Karen N.; Rabaglio, Manuela; Regan, Meredith M.; Smith, Ian (Prof); Thurlimann, B.; Wardley, Andrew; School of Public Health: Public HealthAssessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up, Lancet Oncology, vol.12, 12, 2011,pp 1101-1108
2014Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseBoyle, Frances; Barrios, Carlos; De Azambuja, Evandro; Di Cosimo, Serena; et al, Various; Holmes, Andrew P; Holmes, Eileen; Jackisch, Christian; Lang, Istvan; Perez, E. A.; Piccart-Gebhart, Martine; Smith, Ian (Prof); Swaby, Ramona F; Untch, Michael; Xu, Binghe; Northern Clinical School: MedicineLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response, The Lancet Oncology, vol.15, 10, 2014,pp 1137-1146
2008Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 TrialCoates, Alan; Castiglione-Gertsch, Monica; Chirgwin, Jacquie H; Colleoni, Marco; Crivellari, Diana; Del Mastro, Lucia; Forbes, John F.; Gelber, Richard D. (Prof); Gladieff, Laurence; Goldhirsch, Aron; Lang, Istvan; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Price, Karen; Rabaglio, Manuela; Smith, Ian (Prof); Sun, Zhuoxin; Thurlimann, Beat; School of Public Health: Public HealthLetrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial, Journal of Clinical Oncology, vol.26, 12, 2008,pp 1972-1979
2009Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.Coates, Alan; et al, various; Forbes, John F.; Giobbie-Hurder, Anita; Goldhirsch, Aron; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Price, Karen; Smith, Ian (Prof); Thurlimann, Beat; School of Public Health: Public HealthLetrozole therapy alone or in sequence with tamoxifen in women with breast cancer., New England Journal of Medicine, vol.361, 8,pp 766-776
2015Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyBoyle, Frances; Buzdar, Aman; Ejlertsen, Bent; et al, Various; Fumoleau, Pierre; Gradishar, William; Horick, Nora; Martin, Miguel; Moy, Beverly; O’Shaughnessy, Joyce; Smith, Ian (Prof); Strasser-Weippl, Kathrin; Northern Clinical School: MedicineLong-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy, Breast Cancer Research, vol.17, 1, 2015,pp 1-7